Benzinga | Jan 29, 2021 07:33AM EST

JP Morgan Upgrades Enanta Pharmaceuticals to Neutral, Raises Price Target to $55

JP Morgan analyst Eric Joseph upgrades Enanta Pharmaceuticals (NASDAQ:ENTA) from Underweight to Neutral and raises the price target from $44 to $55.